Affiliation
Oxford Outcomes, an ICON plc Company, Seacourt Tower, West Way, Oxford, OX2 0JJ, UKIssue Date
2012
Metadata
Show full item recordAbstract
Neuroendocrine tumours (NETs) are a rare form of neoplasm that can arise in most organs of the body and which share many common pathologic features. Although curative surgery can be conducted for patients with localised disease, once progression occurs and the disease becomes metastatic or un-resectable, treatment aims to extend life and maintain quality-of-life for as long as possible. The aim of the study was to elicit utilities for health state vignettes describing the burdens associated with receiving therapy for advanced NETs.Citation
Elicitation of health state utilities in neuroendocrine tumours. 2012, 15 (4):681-7 J Med EconJournal
Journal of Medical EconomicsDOI
10.3111/13696998.2012.670175PubMed ID
22364284Type
ArticleLanguage
enISSN
1941-837Xae974a485f413a2113503eed53cd6c53
10.3111/13696998.2012.670175
Scopus Count
Collections
Related articles
- Elicitation of health state utilities in metastatic renal cell carcinoma.
- Authors: Swinburn P, Lloyd A, Nathan P, Choueiri TK, Cella D, Neary MP
- Issue date: 2010 May
- Patient-reported health state utilities in metastatic gastroenteropancreatic neuroendocrine tumours - an analysis based on the CLARINET study.
- Authors: Meng Y, McCarthy G, Berthon A, Dinet J
- Issue date: 2017 Jun 29
- Elicitation of health state utilities in soft tissue sarcoma.
- Authors: Shingler SL, Swinburn P, Lloyd A, Diaz J, Isbell R, Manson S, Benson C
- Issue date: 2013 Sep
- Utilities for treatment-related adverse events in type 2 diabetes.
- Authors: Shingler S, Fordham B, Evans M, Schroeder M, Thompson G, Dewilde S, Lloyd AJ
- Issue date: 2015 Jan
- Estimating health state utilities associated with a rare disease: familial chylomicronemia syndrome (FCS).
- Authors: Matza LS, Phillips GA, Howell TA, Ciffone N, Ahmad Z
- Issue date: 2020 Sep